#Hypertension in #CKD : what do the latest ESH #guidelines recommend ?
📍Target <140/90 in all, <130/80 in most
📍ACEi or ARB if uACR>30
📍SGLT2i if eGFR>20
📍Finerenone in DM if uACR>30, eGFR>25, K<5
📍Chlorthalidone as an option in CKD 4-5 with resistant HTN
#ESH2023
🔴 Finerenone: Questions and Answers—The Four Fundamental Arguments on the New-Born Promising Non-Steroidal MRA
#openaccess #2023Review
mdpi.com/2077-0383/12/1…
#medical #medtwitter #MedEd #cardiotwitter #Cardiology #MedX #CardioEd #cardiology
📌 Optimization of Guideline-Directed Medical Therapies in Patients with #Diabetes and Chronic #Kidney Disease.
👉 🆓 🖇️ t.ly/Mnlu8
#EndoTwitter #MedTwitter #CKD
#SLGT2i #GLP1 #finerenone
For a 50 year old patient with diabetes & chronic kidney disease, combination treatment with SGLT2 inhibitors & finerenone is projected to result in ~5 additional years free from kidney failure Our cross trial analysis of CREDENCE, DAPA-CKD & FIDELIO:
…ubs.pericles-prod.literatumonline.com/doi/10.1111/do…
#FINEARTSHF , the largest trial of an MRA in HFpEF, is now fully enrolled!
6⃣0⃣1⃣6⃣ participants
Many kudos to all investigators & pts worldwide.
Will finerenone achieve the holy grail of MR antagonism: better HF outcomes without excessive hyperkalemia?
clinicaltrials.gov/ct2/show/NCT04…
📌 #Finerenone in chronic kidney disease & type 2 diabetes: the known and the unknown
#CardioRenal #CKD
🔴 Effects of Finerenone on Cardiovascular and Chronic Kidney Diseases: A New Weapon against Cardiorenal Morbidity and Mortality—A Comprehensive #2023Review #openaccess
mdpi.com/2308-3425/10/6…
#cardiology #clinical #MedEd #CardioEd #medtwitter #CardioTwitter #MedTwitter
📢 2023 ESC #Guidelines for the management of pts w/diabetes
🚨 Highlights
👉3 patient profiles (DM+ASCV, DM+HF, DM+CKD)
👉 Prioritize agents w/CV benefit
👉GLP-1RA, SGLT-2is, Finerenone 1️⃣
Finerenone: a mineralocorticoid receptor antagonist (MRA) for the treatment of CKD associated with type 2 diabetes (T2D) ca. 2022 #Nephpearls
tandfonline.com/doi/full/10.10…